Sakurai M, Ichiki M, Hayashi I
Gan To Kagaku Ryoho. 1997 Feb;24(3):303-8.
Phase II study of combination chemotherapy with cisplatin, carboplatin and etoposide (CPVP) was conducted in 46 patients with unresectable non-small cell lung cancer. In the previous paper, we showed that CPVP produced a satisfactory response rate without major toxicities. In the present paper, survival time and prognostic factors were analyzed. The median survival time (MST), 1- and 2-year survival of 46 patients (III A4, III B15, IV 27) were 14.1 months, 57.0% and 18.2%, respectively. In prognostic analysis, responders survived significantly longer than non-responders (MST: 15.8 vs 11.0 months, p < 0.05). Large cell carcinoma and stage IV have proven to be indicators of poor prognosis. Females and patients less than 60 years old tended to do better. With regard to the relationship between the time from initiation of treatment to response and survival time, late responders (response after 3 or 4 courses) survived significantly (p < 0.05) longer than early responders (response after 1 or 2 courses). The CPVP regimen is not only practical, but also very effective. It deserves further study to reveal its advantages compared to the other platinum compound containing regimens.
对46例不可切除的非小细胞肺癌患者进行了顺铂、卡铂和依托泊苷联合化疗（CPVP）的II期研究。在之前的论文中，我们表明CPVP产生了令人满意的缓解率且无严重毒性。在本文中，对生存时间和预后因素进行了分析。46例患者（III A期4例、III B期15例、IV期27例）的中位生存时间（MST）、1年和2年生存率分别为14.1个月、57.0%和18.2%。在预后分析中，缓解者的生存时间明显长于未缓解者（MST：15.8个月对11.0个月，p<0.05）。已证实大细胞癌和IV期是预后不良的指标。女性和年龄小于60岁的患者预后往往较好。关于从开始治疗到出现缓解的时间与生存时间的关系，晚期缓解者（3或4个疗程后出现缓解）的生存时间明显（p<0.05）长于早期缓解者（1或2个疗程后出现缓解）。CPVP方案不仅实用，而且非常有效。与其他含铂化合物方案相比，其优势值得进一步研究以揭示。
